A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Inclusion Criteria:

Signed written informed consent form (ICF)
Patients must be ≥18 years-of-age at the time of signing of the ICF
Female patients must be postmenopausal
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Histologically and/or cytologically confirmed advanced estrogen receptor positive (ER+) human epidermal growth factor 2 negative (HER2-) breast cancer
Patients with life expectancy ≥3 months
Patients who have adequate organ functions at baseline
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 or at least 1 predominantly lytic bone lesion in the absence of measurable disease

Exclusion Criteria:

Treatment with any of the following: systemic anti-cancer chemotherapy, biologic, or hormonal agent from a previous treatment regimen or clinical study within 4 weeks prior to the first dose of AC682; systemic small molecules from a previous treatment regimen or clinical study within 14 days or 5 half-lives (whichever is longer) prior to the first dose of AC682 (at least 10 days must have elapsed between the last dose of such agent and the first dose of study drug)
Radiation therapy such as wide-field radiotherapy administered ≤28 days of first dose of AC682
Major surgery (excluding placement of vascular access) within 4 weeks of first dose of AC682
Known symptomatic brain metastases requiring the use of steroids
Any condition that impairs a patient's ability to swallow whole pills. Impairment of gastrointestinal function (GI) or GI disease or other condition at baseline that will interfere significantly with the absorption, distribution, or metabolism of AC682.
Use of prophylactic growth factors and blood transfusions ≤14 days prior to the first dose of AC682 and during dose limiting toxicity observation period